{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["9(1)"],"submitter":["Madaci L"],"funding":["ADEREM, Marseille, France"],"pubmed_abstract":["After decades during which the treatment of acute myeloblastic leukemia was limited to variations around a skeleton of cytarabine/anthracycline, targeted therapies appeared. These therapies, first based on monoclonal antibodies, also rely on specific inhibitors of various molecular abnormalities. A significant but modest prognosis improvement has been observed thanks to these new treatments that are limited by a high rate of relapse, due to the intrinsic chemo and immune-resistance of leukemia stem cell, together with the acquisition of these resistances by clonal evolution. Relapses are also influenced by the equilibrium between the pro or anti-tumor signals from the bone marrow stromal microenvironment and immune effectors. What should be the place of the targeted therapeutic options in "],"journal":["Biomarker research"],"pagination":["50"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8237443"],"repository":["biostudies-literature"],"pubmed_title":["The contribution of single-cell analysis of acute leukemia in the therapeutic strategy."],"pmcid":["PMC8237443"],"pubmed_authors":["Loriod B","Madaci L","Costello R","Colle J","Venton G","Farnault L"],"additional_accession":[]},"is_claimable":false,"name":"The contribution of single-cell analysis of acute leukemia in the therapeutic strategy.","description":"After decades during which the treatment of acute myeloblastic leukemia was limited to variations around a skeleton of cytarabine/anthracycline, targeted therapies appeared. These therapies, first based on monoclonal antibodies, also rely on specific inhibitors of various molecular abnormalities. A significant but modest prognosis improvement has been observed thanks to these new treatments that are limited by a high rate of relapse, due to the intrinsic chemo and immune-resistance of leukemia stem cell, together with the acquisition of these resistances by clonal evolution. Relapses are also influenced by the equilibrium between the pro or anti-tumor signals from the bone marrow stromal microenvironment and immune effectors. What should be the place of the targeted therapeutic options in ","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Jun","modification":"2025-04-04T09:10:42.293Z","creation":"2022-02-10T17:44:05.918Z"},"accession":"S-EPMC8237443","cross_references":{"pubmed":["34176517"],"doi":["10.1186/s40364-021-00300-0"]}}